
For the treatment of de novo metastatic castration-sensitive prostate cancer improved radiographic progression-free survival and overall survival was seen with the addition of prednisone to androgen-deprivation therapy plus docetaxel.

For the treatment of de novo metastatic castration-sensitive prostate cancer improved radiographic progression-free survival and overall survival was seen with the addition of prednisone to androgen-deprivation therapy plus docetaxel.

In a presentation at the 2021 ESMO Congress, researchers discussed how nivolumab plus ipilimumab showed superior efficacy results after a 5-year follow-up in comparison to single-agent sunitinib.

While they may differ by other genetic alterations, patients with VHL mutated clear cell renal cell carcinoma or VHL wild type ccRCC may have similar characteristics.

Outcomes for patients with mantle cell lymphoma are poor after ibrutinib fails, pointing to a need for the development of safe and effective targeted therapies.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Retrospective research suggests a survival benefit with frontline Sequential crizotinib followed by alectinib in ALK-positive non–small cell lung cancer.

The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

John Diaz, MD, discusses the current results of the phase 1 trial of STRO-002, a novel FRα-targeting antibody-drug conjugate, in patients with ovarian cancer.

An accelerated approval has been granted by the FDA to zanubrutinib, for the treatment of marginal zone lymphoma in patients who have received 1 prior anti-CD20-based therapy.

Durable responses in patients with low-grade upper tract urothelial carcinoma were seen with the mitomycin- containing reverse thermal gel UGN-101.

The current standard of care for BCC is surgical excision. However, the procedure is often time consuming, expensive, and may lead to cosmetic and functional morbidity.

The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

Enrollment has been completed in the VERSATILE-002 trial, a phase 2 study of PDS0101 for the treatment of advanced human papillomavirus-associated head and neck cancer that has returned or spread.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.

Compared to those who are overweight or of a normal weight, patients who are obese are more likely to have better disease-specific and overall survival in metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, John Diaz, MD, discussed the ovarian cancer treatment paradigm and the promise of STRO-002 for an important ovarian cancer subgroup.

The FDA has granted a breakthrough device designation to the NovoTTF-200T System, a tumor treating fields delivery system, for the treatment of unresectable or metastatic liver cancer.

Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Data from an exploratory analysis of the phase 3 IMpower010 trial show the disease-free survival benefit of adjuvant atezolizumab in the treatment of early-stage non–small cell lung cancer.

The first patient has been dosed in the phase 1b/2 trial of ERAS-007, an extracellular signal-regulated kinase inhibitor, for the treatment of advanced non-small cell lung cancer.

Onvansertib has demonstrated positive efficacy and safety in patients with KRAS-mutant metastatic colorectal cancer.

The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, was safe and effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma carrying chromosome 17p13.1 deletion.

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

In an interview with Targeted Oncology, Michael Kolodziej, MD, the senior advisor for ADVI Health as well as an American College of Physicians Fellow, discussed the impact the COVID-19 pandemic has had on oncology practice.

The addition of ramucirumab to gemcitabine in the second-line setting led a survival advantage for patients malignant pleura mesothelioma.